Back to discover
Disease

HIV Infections

Late-stage therapeutic developmentActively researchedRising momentum
32
Publications
22
Clinical trials
9
Related conditions
1
Related proteins
2025
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Immune checkpoint inhibitors in infectious disease.

Research2024-09-09Immunological reviews

Inflammatory and Immune Mechanisms for Atherosclerotic Cardiovascular Disease in HIV.

Research2024-07-01International journal of molecular sciences

The immune response to SARS-CoV-2 in people with HIV.

Research2023-10-11Cellular & molecular immunology

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 1 regulatory approval from EMA on record.
  • 2 clinical trials expected to report results, the earliest in Q3 2026.
  • Active recent publication activity.
Major developments
Important regulatory approvalHigh impact
Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.2026-04-27
Research Highlights1View
Clinical Milestones5View
Regulatory Updates1View
  • 2026-04-27Approval — MavorixaforXolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.
Activity timeline7

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Mavorixaforapproved

Approval — Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syn… (2026)

Approval — Treatment Ertapenem SUN is indicated in paediatric patients (3 months to 17 years of age)… (2022)

Tecovirimatapproved

Approval — Tecovirimat SIGA is indicated for the treatment of the following viral infections in adul… (2022)

Approval — Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM)… (2020)

Tigecyclineapproved

Approval — Tygecycline Accord is indicated in adults and in children from the age of eight years for… (2020)

Delafloxacinapproved

Approval — Quofenix is indicated for the treatment of the following infections in adults: acute bac… (2019)

Posaconazoleapproved

Approval — Posaconazole Accord is indicated for use in the treatment of the following fungal infecti… (2019)

Clinical trials

11 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
22
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2026emaApprovalMavorixafor· Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. source ↗
2022emaApprovalErtapenem sodium· Treatment Ertapenem SUN is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4.4 and 5.1): Intra-abdominal infections Community acquired pneumonia Acute gynaecological infections Diabetic foot infections of the skin and soft tissue (see section 4.4) Prevention Ertapenem SUN is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4.4). Consideration should be given to official guidance on the appropriate use of antibacterial agents. source ↗
2022emaApprovalTecovirimat· Tecovirimat SIGA is indicated for the treatment of the following viral infections in adults and children with body weight at least 13kg: Smallpox Cowpox Tecovirimat SIGA is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13kg . Tecovirimat SIGA should be used in accordance with official recommendations. source ↗
2020emaApprovalAmikacin sulfate· Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. source ↗
2020emaApprovalTigecycline· Tygecycline Accord is indicated in adults and in children from the age of eight years for the treatment of the following infections (see sections 4.4 and 5.1): Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections (see section 4.4) Complicated intra-abdominal infections (cIAI) Tygecycline Accord should be used only in situations where other alternative antibiotics are not suitable (see sections 4.4, 4.8 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents. source ↗
2019emaApprovalDelafloxacin· Quofenix is indicated for the treatment of the following infections in adults: acute bacterial skin and skin structure infections (ABSSSI), community-acquired pneumonia (CAP), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4.4 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents. source ↗
2019emaApprovalPosaconazole· Posaconazole Accord is indicated for use in the treatment of the following fungal infections in adults: Invasive aspergillosis; Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B; Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole; Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. Posaconazole Accord is also indicated for prophylaxis of invasive fungal infections in the following patients:  Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections; Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. source ↗
2019emaApprovalPosaconazole· Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults: Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products; Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B; Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole; Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients: Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections; Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

32 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20062025
Most influential
Recent publications
Major themes8
  • HIV Infections22
  • COVID-194
  • HIV-13
  • Extracellular Vesicles2
  • Immune Checkpoint Inhibitors2
  • Neoplasms2
  • Acquired Immunodeficiency Syndrome1
  • Aging1
Leading journals6
  • International journal of molecular sciences3
  • Circulation research2
  • Frontiers in immunology2
  • Immunological reviews2
  • Microbiome2
  • Molecular neurobiology2
Leading researchers8
  • Clifford DB2
  • Ellis RJ2
  • Gelman BB2
  • Letendre SL2
  • Lewin SR2
  • Marra CM2
  • Abbar B1
  • Abramson I1
Affiliations (unnormalised)6
  • University of California San Diego3
  • London School of Hygiene and Tropical Medicine2
  • School of Medicine2
  • University of Cape Town2
  • Washington University in St. Louis2
  • "L. Spallanzani" National Institute for Infectious Diseases (INMI)1

Disease biology

1 match

Key proteins & gene products studied in this disease. Number shows shared papers.

Related conditions

9 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

HIV infections comprise a spectrum of disease caused by human immunodeficiency virus, ranging from asymptomatic seropositivity through AIDS-related complex to acquired immunodeficiency syndrome (AIDS). The literature grounding emphasizes the infection’s chronic course, its immunologic consequences, and its complications, mortality, microbiology, virology, and epidemiology.

Causes

The grounding supports human immunodeficiency virus as the cause of the infection. It also links transmission-related context to sexual behavior and male homosexuality in the literature, but does not provide a fuller etiologic breakdown beyond HIV infection itself.

Pathophysiology

HIV infection is characterized by persistent viral infection with host-pathogen interactions that drive immune dysfunction. The supplied reviews highlight chronic antigen exposure leading to T-cell exhaustion, maintenance of latently infected reservoirs, and dysregulation of cytokines and chemokines that can contribute to inflammatory injury. Microglial cells are described as a major latent HIV-1 reservoir in the brain, linking infection to central nervous system involvement and HIV-associated neurocognitive disease.

Risk factors

The grounding indicates that sexual behavior, including male homosexuality, is a studied epidemiologic context for HIV infection. It also suggests that exposure to sexually transmitted infections is relevant in HIV prevention settings, but it does not support a broader list of risk factors.

Current standard of care

The supplied material supports antiretroviral therapy, including combination antiretroviral therapy, as the core treatment modality for HIV infection. It also mentions HIV preexposure prophylaxis in prevention-focused literature, but does not provide treatment regimens or other specific drug classes beyond antiretroviral therapy.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.